Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 23:56 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Augmenting Effects of L-DOPS With Carbidopa and Entacapone
NCT00547911 · National Institute of Neurological Disorders and Stroke (NINDS) · PHASE1/PHASE2 · terminated · last registry update 2014-07-17 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Study terminated due to contamination droxidopa” | – | Registry record, National Institute of Neurological Disorders and Stroke (NINDS) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision